Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Platelet Rich Plasma for Musculoskeletal Conditions

NCT: NCT07231471 · RECRUITING

NCT IDNCT07231471
StatusRECRUITING
Start Date2025-12-29
Completion2035-01-01

Brief Summary

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction. This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Frequently Asked Questions

What is Platelet Rich Plasma for Musculoskeletal Conditions?

Platelet Rich Plasma for Musculoskeletal Conditions is a clinical trial registered under NCT07231471. Current status: RECRUITING.

What is the status of NCT07231471?

The current status of NCT07231471 (Platelet Rich Plasma for Musculoskeletal Conditions) is: RECRUITING.

When did Platelet Rich Plasma for Musculoskeletal Conditions start?

Platelet Rich Plasma for Musculoskeletal Conditions started on 2025-12-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.